Latest filing published 17 Aug 2022 for Insight Molecular Diagnostics Inc., €9,832.
Filing timeline
BuySaleInsider track record
No signal scores available.
Closed purchases
Not enough history yet: 1 closed purchase, at least 2 are needed.
Purchases by company
Since each purchase
- -80.1%Entry US$18.40 · Close at T+365 US$3.66
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Melinda Griffith: trading record in brief
Melinda Griffith discloses dealings in Insight Molecular Diagnostics Inc. to SEC (Form 4). In total, 3 filings cover trades dated from 24 June 2022 to 16 August 2022.
No open-market sale appears; the market trades are 1 purchase worth €9,832. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Outside the open market, there are 1 share grant and 1 option exercise.
Most recently, on 17 August 2022, the filings show an open-market purchase worth €9,832 in Insight Molecular Diagnostics Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. For comparison, the SEC allows two business days to file a Form 4. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to Melinda Griffith
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 10,000 shares@ US$1.00100.0% of flowCommon Stock, no par valueSEC:0001493152-22-023378:1Canonical exit: 14 Nov 2022 (T+90)
- 10,000 shares0Common Stock, no par valueSEC:0001493152-22-023378:0
- 10,000 shares0Common Stock, no par valueSEC:0001493152-22-019819:0
3 of 3 declarations
